Commercializing Living Therapies with CCRM
Hear from academic and industry experts sharing insider insights, information and trend forecasts for the cell and gene therapy industry. “Commercializing Living Therapies with CCRM” is brought to you by CCRM, a leader in developing, manufacturing and commercializing regenerative medicine-based technologies, and cell and gene therapies. Questions / comments? email: podcast@ccrm.ca.
Episodes
20 episodes
Unapproved stem cell therapies: Risks, realities and responsibilities
Featuring:Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of MedicineAmy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina***
•
Season 4
•
Episode 2
•
35:30
Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies
Featuring:Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, OracleKenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. ***We are excited to sh...
•
Season 4
•
Episode 1
•
34:59
Expert insights for taking a cell or gene therapy company from vision to reality
Featuring:Jacki Jenuth, PhD, Partner and COO, Lumira VenturesRobin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM***In this episode, we explore the dynamics of venture capital (...
•
Season 3
•
Episode 6
•
26:25
Regulators' strategies for managing the surge in cell and gene therapies
Featuring:Michael Rosu-Myles, PhD, Executive Director, Health CanadaJosephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine***Currently, there are more than 2,000 c...
•
Season 3
•
Episode 5
•
27:35
How Creative Destruction Lab accelerates the advanced therapies industry
Featuring:Sonia Sennik, Executive Director, Creative Destruction LabGlenn MacLean, Director, Technology Sourcing and Venture Development, CCRM***In many science-oriented fields, including regenerative medicin...
•
Season 3
•
Episode 4
•
24:23
The synergy solution: How public-private partnerships advance regenerative medicine
Featuring:Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy CatapultMichael May, PhD, President and Chief Executive Officer, CCRM***Public-private partnerships are collaborations between governmen...
•
Season 3
•
Episode 3
•
34:43
Catalysts of change: Canada’s research hubs are shaping the future of biomanufacturing
Featuring:Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Director, St...
•
Season 3
•
Episode 2
•
33:24
From code to cure: Exploring the synergies of artificial intelligence and regenerative medicine
Featuring:Mamatha Bhat MD, MSc, PhD, FRCPCHepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health NetworkAssociate ...
•
Season 3
•
Episode 1
•
33:23
Stuck in the sixties: The fight to fast-forward access to better cancer treatment
Featuring:Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hea...
•
Season 2
•
Episode 6
•
27:24
CAR T therapies: Engineering immune cells to treat cancer
Featuring:Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Me...
•
Season 2
•
Episode 5
•
31:10
Protecting the product of innovation: IP and commercialization in cell and gene therapies
Featuring:Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch TherapeuticsIn the past, there was little evidence to chal...
•
Season 2
•
Episode 4
•
34:23
Mentoring: making moves to maximize career growth
Featuring:Dr. Dolores Baksh, CEO of TAAV Biomanufacturing SolutionsSusan Nichols, Chief Business Officer at ViroCell BiologicsAs the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Nichols emp...
•
Season 2
•
Episode 3
•
27:53
Unlocking the potential of induced pluripotent stem cells
Featuring: Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT) Drs. Lise Munsie and Stephen Sullivan explore some of the...
•
Season 2
•
Episode 2
•
27:31
Training tomorrow’s talent: building the biomanufacturing workforce
Featuring: Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London (UCL)Dr. Christine Allen, Vice-President, Ecosystem Development, adMare BioInnovationsDrs. Chr...
•
Season 2
•
Episode 1
•
23:05
You get what you pay for
How will Canada’s health care system pay for cell and gene therapy cures? Featuring: Dr. Chris McCabe, CEO and Executive Director, Institute of Health Economics Robert Woolstencroft, Senior Director and Hea...
•
Season 1
•
Episode 6
•
35:21
A busy intersection: Ethics and policy in cell and gene therapies
Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future.Featuring: Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of ...
•
Season 1
•
Episode 5
•
35:25
The Future’s Synthetic
Looking to the future of synthetic biology in cell and gene therapies. Featuring: Dr. George Church, Professor of Genetics, Harvard Medical School Dr. Peter Zandstra C.M., Director and Professor, School of Biomedic...
•
Season 1
•
Episode 4
•
25:23
Moving from A to B
Manufacturing and supply chain issues in cell and gene therapies. Featuring: Dr. Anthony Davies, Founder and CEO, Dark Horse Consulting Rob Jones, Vice President, Global Bioservices, Cryoport Systems <...
•
Season 1
•
Episode 3
•
31:10
